Pyxis Oncology, Inc. (PYXS) vs Zentalis Pharmaceuticals, Inc. (ZNTL)

Pyxis Oncology, Inc. and Zentalis Pharmaceuticals, Inc. are both Biotechnology companies. Pyxis Oncology, Inc. and Zentalis Pharmaceuticals, Inc. are of similar size ($260.4M and $250.2M). Across the 8 metrics below, Zentalis Pharmaceuticals, Inc. leads on 5 and Pyxis Oncology, Inc. on 3.

Valuation

Metric PYXS ZNTL Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 16.00 1.34 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m n/m 10.73
Earnings yield (49.30%) (72.22%) (28.84%)
Free cash flow yield (37.11%) (66.47%) (23.03%)

Profitability

Metric PYXS ZNTL Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (179.10%) (66.75%) (57.72%)
Return on assets (99.62%) (49.22%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PYXS ZNTL Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 3.03% 18.03% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PYXS ZNTL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.34 4.82 4.73
Net debt to EBITDA 0.82 1.59 0.96

Dividend

Metric PYXS ZNTL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PYXS ZNTL Biotechnology median
Market cap 250.22m 260.35m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack